Bringing expensive medicines within reach
Powered by in-depth research, Hervycta® is equipped to create value through user centric innovations.
At Dr. Reddy’s, we are constantly looking for opportunities that allow us to bring expensive medicines within the reach of millions around the world. The belief that Good Health Can’t Wait inspires us to delve deep into understanding the needs of patients and do all that it takes to fulfil them.
Our recent launch of Hervycta®, Dr. Reddy’s brand of trastuzumab in India, is a testimony to our objective of offering solutions for these unmet patient needs which will benefit women suffering from breast cancer in India. Hervycta® (Trastuzumab), a biosimilar of Roche’s Herceptin® in India, is indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).
Powered by in-depth research, this biosimilar is equipped to create value through user centric innovations.
Commenting on the launch, M V Ramana, CEO- Branded Markets (India and Emerging Markets), said, “We strive every day to do what matters most for patients. Hervycta® is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space.
Click to read more